INmune Bio attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan Co-founder and CEO R.J. Tesi and Director of Neuroscience C.J. Barnum both participated in talks about the role of immunotherapy in the treatment of specific medical conditions The congress was a paramount event in the field of immunotherapy, allowing … Continue reading “INmune Bio Inc. (NASDAQ: INMB) Presents Cancer Treatment Immunotherapy at Congress of International Drug Discovery Science & Technology”
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its Co-Founder and CEO RJ Tesi, M.D. will present at the Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit. The event is taking place in Boston from August 5 through … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Co-Founder and CEO to Present at Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit”
California-based INmune Bio is developing therapies to battle cancers and Alzheimer’s disease by more effectively engaging the body’s own natural defenses Research published in a peer-reviewed scientific journal shows a mechanism by which scientists can track and strategize natural killer cell promotion as an innate physical response to cancer in lieu of other pharmaceutical inducements … Continue reading “Research Highlights Virtues of INmune Bio Inc.’s (NASDAQ: INMB) Strategy in Fighting Cancer with Body’s Own Natural Cells”
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its Director of Neuroscience, C.J. Barnum, and Co-Founder and CEO, R.J. Tesi, M.D., will present at the 17th Annual Congress of International Drug Discovery Science & Technology. The event, scheduled … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at 17th Annual Congress of International Drug Discovery Science & Technology 2019”
INmune Bio (NASDAQ: INMB) is an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, such as Alzheimer’s disease (“AD”). A recent article discussing the company reads, “An association between inflammation and Alzheimer’s disease has long been established. Until present, however, this link and the way in which … Continue reading “NetworkNewsBreaks – INmune Bio Inc.’s (NASDAQ: INMB) Innovative Drug Candidate Targets Neuroinflammation to Treat Alzheimer’s Disease”
Research indicates that anti-inflammatory medications have the power to prevent the onset and control the symptoms of Alzheimer’s disease The link between inflammatory processes and Alzheimer’s has long been established; companies like INmune Bio are working to further the research and develop safe and effective drugs based on disrupting this mechanism INmune Bio has received … Continue reading “TNF Inhibitors Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595 May Reduce the Risk of Alzheimer’s Development, Report Suggests”
Companies like INmune Bio are advancing the development of innovative treatment methods INmune’s lead drug candidate, XPro1595, works by targeting neuroinflammation, one of the causes of Alzheimer’s XPro1595 is set to undergo a phase I clinical trial in the summer of 2019 with a goal of measuring traditional and novel biomarkers of inflammation in patients … Continue reading “Alzheimer’s Disease Market Growth Driven by Innovative Developments Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595”
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its co-founder and CEO, R.J. Tesi, M.D., presented at the Maxim Group’s conference on Alzheimer’s disease on June 26 in New York. According to the update, Tesi’s presentation addressed … Continue reading “NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Co-Founder and CEO Showcases XPro1595 at Maxim Group’s Conference on Alzheimer’s Disease”
Diversified clinical-stage immunology company INmune Bio (NASDAQ: INMB) is on a mission to develop novel immunotherapies that reprogram patients’ innate immune systems to enable them to fight cancer and Alzheimer’s disease. A recent article further discussing the company reads, “Innate is an immediate, nonspecific, initial response that serves as a first line of defense against … Continue reading “NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) at the Forefront of Modernizing Immunology”
INmune Bio (NASDAQ: INMB), a diversified clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to combat disease, is currently developing drug candidates INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease. An article further discussing the company … Continue reading “NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Developing Innovative Drug Candidates to Treat Cancer, Alzheimer’s Disease”
